Virginia Jamieson is returning as the chief medical officer of Swiss biotechnology firm Kuros Biosciences (SIX: CYTN), it was announced on Tuesday.
Dr Jamieson, who also becomes a member of the executive board, worked for Kuros previously from 2005 to 2012.
She has spent more than 25 years in the pharmaceutical industry and has a wealth of experience in early and late stage clinical development, product registration and medical affairs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze